Chemical Screening of RIKEN Natural Products Depository Identified a MYCN Expression Inhibitor Partially through HGF–MET Signaling Pathway

ACS Chemical Biology 2026

View at publisher
Authors: Yali Xu, Hricha Mishra, Hiroyuki Osada, Nobumoto Watanabe, Hiroyuki Hirano, Hajime Nishimura, Yutaka Furutani, Yusuke Suenaga, Yoshitaka Hippo, Wenkui Yu, Harukazu Suzuki, Xian‐Yang Qin
DOI: 10.1021/acschembio.5c00675
Cited by: 1
References: 46

Abstract

suppression. Notably, MI102 effect exhibited superior tumor cell selectivity compared with the MET inhibitor tivantinib. At the transcriptional level, RNA-seq revealed that MI102 globally downregulated MYCN-associated oncogenic programs. Collectively, these findings establish pharmacological downregulation of MYCN as a promising therapeutic strategy for HCC and reveal a functional link between MET signaling and MYCN-driven oncogenic pathways.

Fields of Study & Subjects

Liver physiology and pathology Fibroblast Growth Factor Research Cancer Mechanisms and Therapy

Publication details

Journal / source
ACS Chemical Biology
Publisher
American Chemical Society (ACS)
Volume
21
Issue
2
Pages
253–262
Publication date
21 January 2026
Language
EN